Neurizon Therapeutics Ltd. Announces Promising Preclinical Results for NUZ-001 in Zebrafish Model of Huntington's Disease
Reuters
Jun 16, 2025
Neurizon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Ltd. Announces Promising Preclinical Results for NUZ-001 in Zebrafish Model of Huntington's Disease
Neurizon Therapeutics Ltd., a clinical-stage biotech company, has announced promising preclinical results for their drug candidate NUZ-001 in a zebrafish model of Huntington's disease. The study demonstrated that NUZ-001 and its active metabolite, NUZ-001 Sulfone, exhibited significant neuroprotective effects. The treatment successfully prevented developmental and morphological abnormalities, protected against neuronal cell death, restored haemoglobin production, and rescued BDNF expression following the knockdown of the Htt protein. These findings underscore NUZ-001's potential as a platform therapy targeting core neurodegenerative mechanisms. Neurizon plans to initiate additional validation studies in mammalian models of Huntington's disease to further explore its therapeutic potential. These results were presented on June 16, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10836) on June 16, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.